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Abstract
In prion diseases, synapse dysfunction, axon retraction and loss of neuronal polarity pre-
cede neuronal death. The mechanisms driving such polarization defects, however, remain
unclear. Here, we examined the contribution of RhoA-associated coiled-coil containing
kinases (ROCK), key players in neuritogenesis, to prion diseases. We found that overacti-
vation of ROCK signaling occurred in neuronal stem cells infected by pathogenic prions
(PrPSc) and impaired the sprouting of neurites. In reconstructed networks of mature neu-
rons, PrPSc-induced ROCK overactivation provoked synapse disconnection and dendrite/
axon degeneration. This overactivation of ROCK also disturbed overall neurotransmitter-
associated functions. Importantly, we demonstrated that beyond its impact on neuronal
polarity ROCK overactivity favored the production of PrPSc through a ROCK-dependent
control of 3-phosphoinositide-dependent kinase 1 (PDK1) activity. In non-infectious condi-
tions, ROCK and PDK1 associated within a complex and ROCK phosphorylated PDK1,
conferring basal activity to PDK1. In prion-infected neurons, exacerbated ROCK activity
increased the pool of PDK1 molecules physically interacting with and phosphorylated by
ROCK. ROCK-induced PDK1 overstimulation then canceled the neuroprotective α-cleav-
age of normal cellular prion protein PrPC by TACE α-secretase, which physiologically pre-
cludes PrPSc production. In prion-infected cells, inhibition of ROCK rescued neurite
sprouting, preserved neuronal architecture, restored neuronal functions and reduced the
amount of PrPSc. In mice challenged with prions, inhibition of ROCK also lowered brain
PrPSc accumulation, reduced motor impairment and extended survival. We conclude that
ROCK overactivation exerts a double detrimental effect in prion diseases by altering
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neuronal polarity and triggering PrPSc accumulation. Eventually ROCK emerges as thera-
peutic target to combat prion diseases.
Author Summary
Transmissible Spongiform Encephalopathies (TSEs), commonly named prion diseases, are
caused by deposition in the brain of pathogenic prions PrPSc that trigger massive neuronal
death. Because of our poor understanding of the mechanisms sustaining prion-induced
neurodegeneration, there is to date no effective medicine to combat TSEs. The current
study demonstrates that ROCK kinases are overactivated in prion-infected cells and con-
tribute to prion pathogenesis at two levels. First, PrPSc-induced ROCK overactivation
affects neuronal polarity with synapse disconnection, axon/dendrite degradation, and dis-
turbs neuronal functions. Second, ROCK overactivity amplifies the production of patho-
genic prions. The pharmacological inhibition of ROCK protects diseased neurons from
PrPSc toxicity by preserving neuronal architecture and functions and lowering PrPSc level.
Inhibition of ROCK in prion-infected mice reduces brain PrPSc levels, improves motor
activity and extends lifespan. This study opens up new avenues to design ROCK-based
therapeutic strategies to fight TSEs.
Introduction
In neurodegenerative disorders including Transmissible Spongiform Encephalopathies (TSEs),
it is now admitted that neuronal death is a late event in the neurodegenerative process preceded
by an early loss of neuronal polarity at the root of behavioral and cognitive deficits [1–4]. In
TSEs, synapse retraction and progressive axonal degeneration correlate with brain accumula-
tion of the scrapie protein (PrPSc), which is the essential component of infectious prions [5].
PrPSc is an abnormally folded self-propagating isoform of cellular prion protein (PrPC), a phys-
iological cell-surface glycosylphosphatidylinositol(GPI)-anchored protein. The neurotoxic
effects of PrPSc depend on the neuronal expression of PrPC since the suppression of PrPC in
neurons of infected mice, just prior to the clinical phase, hampers PrPSc-induced neuronal loss
[6–8]. For instance, prion-associated neurotoxicity relates to subversion of PrPC function(s) in
neurons following the conversion of PrPC into PrPSc [9–12].
From a physiological point of view, by acting as a signaling and/or a scaffolding molecule,
PrPC plays a central role in neuritogenesis able to promote the sprouting, outgrowth and main-
tenance of neurites [13,14]. PrPC involvement in the very initial phase of neuritogenesis is sup-
ported by the observation that siRNA-mediated PrPC silencing in 1C11 neuronal stem cells or
PC12 cells (PrPnull-cells) impairs neurite sprouting accompanying neuronal differentiation
[15]. This PrPC role relies on its capacity to control the signaling activity of plasma membrane
β1 integrins, the downstream activity of RhoA-associated coiled-coil containing kinases
(ROCK) and the dynamics of actin microfilaments [15]. In the absence of PrPC, overactivated
ROCK reduces the turnover of actin fibers and exerts a dominant negative effect on the sprout-
ing of neurites [15]. In differentiating and mature neurons, PrPC influences neurite outgrowth
and maintenance as well as synapse connectivity through its interaction with a set of diverse
partners (N-CAM, STI-1, laminin γ-1, mGluR1-5, α7-nAChR) depending on the neuronal
type [16–21] and the fine-tuning of Rho-GTPase and ROCK activities [14]. Besides, because
neuritogenesis is intimately linked to the expression of neuronal functions, ROCK may hence
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take part to the onset, regulation and integration of neurotransmitter-associated functions.
Whether PrPSc-mediated corruption of the functional relationship between PrPC and ROCK
accounts for neuronal polarity alterations and abnormal neuronal functions, and contributes
to TSEs progression, remains unknown.
To address these issues, we mainly exploit the properties of the 1C11 neuroectodermal cell
line, which is endowed with the capacity to develop neurites and to acquire all functional prop-
erties of serotonergic neurons (1C115-HT) within four days upon appropriate induction [22],
and is chronically infected by mouse-adapted prions derived from scrapie (22L) or a human
familial prion disease (Fukuoka-1, Fk) [23]. We previously reported that prion infection dis-
turbs all neurotransmitter-associated functions in prion-infected 1C115-HT neuronal cells and
triggers the production of neurotoxins, i.e. oxidative derivatives of serotonin [23]. In this study,
we also take advantage of primary cultures of mature cerebellar granule neurons and of a cor-
tico-striatal neuronal network reconstructed on microfluidic chips to assess the impact of
prion infection on synapse connectivity and neurite integrity. We show here that prion infec-
tion impairs the development of neurites in the 1C11 neuronal stem cell line and triggers syn-
apse disconnection and neurite degeneration in primary cultures of neurons. Defects in
neuronal polarity originate from prion-induced overactivation of ROCK activity. Antagonizing
ROCK activity rescues neurite sprouting of prion-infected 1C11 cells and protects prion-
infected mature neurons from neurite degeneration. The beneficial effect afforded by ROCK
inhibition on neuronal polarization is associated with restoration of neurotransmitter-associ-
ated functions and decrease of serotonin-derived neurotoxins levels.
Importantly, ROCK overactivation contributes to TSEs pathogenesis by stimulating the
conversion of PrPC into PrPSc. We recently evidenced that PrPSc formation relates to a defect
of cell surface TACE α-secretase neuroprotective activity towards PrPC caused by the overacti-
vation of the 3-phosphoinositide-dependent kinase 1 (PDK1) [24]. We demonstrate here that
ROCK interact with and phosphorylate PDK1 leading to PDK1 overactivation in prion-
infected cells. Inhibition of ROCK disrupts the ROCK-PDK1 complex, lowers PDK1 activity,
rescues TACE activity at the plasma membrane and induces strong reduction of PrPSc level in
prion-infected neuronal cells. Finally, inhibiting ROCK in mouse models of prion infection
mitigates prion diseases.
Results
Prion infection of 1C11 neuronal stem cells impairs the onset of neurites
through a ROCK-dependent mechanism
When Fk- or 22L-infected 1C11 precursor cells were induced to differentiate towards the sero-
tonergic program, less than 20% of Fk- and 22L-infected cells converted into neuronal-like
cells with small, rounded cell bodies and bipolar extensions undistinguishable from uninfected
1C115-HT neuronal cells. The other 80% fraction did not adopt a neural-like morphology and/
or presented spindle shaped cell bodies harboring wide and short extensions (Fig 1A).
These defects in neuronal polarization recall the impairment of neurite sprouting caused by
PrPC silencing in 1C11 progenitors and PC12 cells [15]. We previously showed that PrPC
depletion triggers the clustering and overactivation of β1 integrins, which in turn promote
overactivation of the RhoA-ROCK-LIMK-cofilin pathway leading to alterations of F-actin
architecture and subsequent gain of cell contractility [15]. In line with this, cell surface PrPC
immunolabeling under native conditions revealed that more than 90% of Fk-infected cells dis-
played very little fluorescence, while uninfected 1C11 cells stained brightly and uniformly (Fig
1B). This suggests a thorough conversion of cell surface PrPC into PrPSc and in fine depletion
of PrPC molecules normally present at the plasma membrane of infected cells. PrPSc
ROCKOveractivity in Prion Diseases
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Fig 1. Prion infection of 1C11 neuronal stem cells alters neuritogenesis by overactivating the RhoA-ROCK-LIMK-cofilin pathway andmodifying
the actin network. (A) Phase pictures and cell contour staining with anti-tetraspanin CD9 antibody of Fk- or 22L-infected 1C115-HT cells as compared to
uninfected neuronal 1C115-HT cells (day 4). Scale bars, 50 μm. (B) Immunofluorescent labeling of PrPC, PrPSc and activated β1 integrins at the surface of Fk-
infected 1C11 cells as compared to their uninfected counterparts using SAF32, ICSM33 and 9EG7 antibodies, respectively. Immunofluorescent labeling of
phospho-LIMK1/2 on Thr508/505 residues and phospho-cofilin on Ser3 and F-actin staining using TRITC-phalloidin within Fk-infected and uninfected 1C11
ROCKOveractivity in Prion Diseases
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immunolabeling with PrPSc reacting ICSM33 antibody [25] under denatured conditions with
guanidine thiocyanate indeed showed a high level of PrPSc in Fk-infected 1C11 cells (Fig 1B).
PrPC conversion into PrPSc had no impact on total β1 integrin expression level as assessed
by western blotting using the anti-CD29 antibody (Fig 1C). Nevertheless, cell surface immuno-
fluorescence analyses using a β1 integrin antibody (9EG7) specifically targeting activated β1
integrins revealed that the pool of activated integrins was ~2-fold increased in Fk-infected cells
as compared to uninfected 1C11 cells (Fig 1B). In addition, active β1 integrins were evenly dis-
tributed and displayed a dot-like staining at the cell periphery of uninfected 1C11 cells, while
they clustered and formed elongated patches in Fk-infected 1C11 cells (Fig 1B).
As compared to uninfected cells, we measured increases by 2- to 3-fold in RhoA GTPase
activity (Fig 1C), the phosphorylation level of LIMK1/2 on Thr505 and Thr508 (Fig 1B and
1C), and the phosphorylation level of cofilin on Ser3 (Fig 1B and 1C) in Fk- and 22L-infected
1C11 cells, indicating that prion infection reduces cofilin-associated severing activity towards
F-Actin [26–29]. Accordingly, fibrillar actin (F-actin) microfilaments were large and disorga-
nized in the cytoplasm of Fk-infected 1C11 cells, while F-actin distributed as thin, parallel
stress fibers underneath the cell plasma membrane of uninfected 1C11 precursor cells (Fig 1B).
These overall data show that prion infection triggers overactivation of the RhoA-ROCK-
LIMK-cofilin signaling pathway, which alters the architecture and turnover of F-actin microfil-
aments, thereby contributing to neuritogenesis impairment.
ROCK inhibition in prion-infected 1C11 cells restores neuritogenesis and
rescues overall neurotransmitter-associated functions
We next wondered whether inhibiting ROCK activity would counteract prion-induced neuri-
togenesis defects. When treated with two distinct ROCK inhibitors, namely Y-27632 (100 μM)
or dimethylfasudil (2 μM) (for review see [30–32] and references therein), ~90% of Fk- or 22L-
infected 1C11 cells induced to differentiate along the serotonergic pathway developed neurites.
At the end of the program (day 4), prion-infected 1C11 cells differentiated in the presence of
ROCK inhibitors (referred to as Rocki-infected 1C115-HT cells) exhibited neurites that were
thin, bipolar and extended from the ovoid cell body as for uninfected 1C115-HT neuronal cells
(S1 Fig and S1 Table). The mean neurite length of Rocki-infected 1C115-HT cells was compara-
ble to that of uninfected 1C115-HT cells differentiated in the presence of ROCK inhibitors (S1
Table). Rescued neuritogenesis by Fk-infected 1C11 precursor cells upon ROCK inhibition was
associated with decrease to basal level of phospho-cofilin level on Ser 3 (Fig 2A), which restores
cofilin severing activity towards F-actin and renders Fk-1C11 precursor cells competent to
sprout neurites when induced towards the neuronal program [15].
Beyond the rescue of neuronal polarity, inhibition of ROCK restores the overall neuronal
functions, i.e. synthesis, storage, degradation and transport of 5-HT, in Rocki-infected
1C115-HT cells. While the activity of tryptophan hydroxylase (TPH), the 5-HT synthesizing
enzyme, in Fk-1C115-HT cells represented 5% of that measured with uninfected 1C115-HT cells,
TPH activity increased by 8- to 18-fold in Rocki-Fk-1C115-HT cells treated with Y-27632 or
dimethylfasudil, respectively (Fig 2B). Corroborating TPH activity, western blot analysis
revealed that the TPH2 enzyme was weakly present in Fk-1C115HT cells compared to unin-
fected 1C115-HT cells, while TPH2 expression was recovered in Rocki-Fk-1C115-HT cells (Fig
2B). This indicates that PrPSc-induced ROCK overactivation impairs TPH protein synthesis.
cells. Scale bars, 50 μm. (C) Western blots for total level of β1 integrins, phosphorylated LIMK1/2 and phosphorylated cofilin in 1C11 and Fk-1C11 cells.
RhoA GTPase activity measured by pull-down assay in 1C11 and Fk-1C11 cells. Quantitative data are shown as the mean ± s.e.m. * P < 0.01 versus
uninfected cells. # P < 0.05 versus uninfected cells.
doi:10.1371/journal.ppat.1005073.g001
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Fig 2. Inhibition of ROCK restores neurotransmitter-associated functions in prion-infected 1C115-HT neuronal cells. (A) Western blot and histogram
quantifications for phosphorylated cofilin on Ser3 in Fk-infected 1C11 cells treated or not with dimethylfasudil (2 μM) or Y-27632 (100 μM) for 1h versus
uninfected 1C11 cells. (B) 5-HT synthesis (TPH activity) and TPH immunoblotting, (C) transport by SERT (paroxetine binding) and SERT immunoblotting,
(D) storage (VMAT-2 tetrabenazine binding), (E) intracellular content, and (F) catabolism (5-HIAA concentration) in uninfected 1C115-HT cells and Fk-infected
1C115-HT cells differentiated for 4 days along the serotonergic pathway in the absence or presence of Y-27632 (100 μM) or dimethylfasudil (2 μM). (G)
Concentration of 5-HT-derived oxidized species in cell lysates of 1C115-HT cells and Fk-1C115-HT differentiated in the absence or presence of Y-27632 or
dimethylfasudil. n = 6 for each condition. Values are the mean ± s.e.m. # P < 0.05 versus uninfected cells. ## P < 0.05 versus infected cells.
doi:10.1371/journal.ppat.1005073.g002
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Using the paroxetine Serotonin Re-uptake Inhibitor (SRI) antidepressant to count func-
tional Serotonin Transporter (SERT) molecules [33], we showed that the number of functional
SERT proteins was 5- (Y-27632) to 7- (dimethylfasudil) fold enhanced in Rocki-Fk-1C115-HT
cells as compared to Fk-1C115-HT cells (where functional SERT level was 10% of that measured
with uninfected 1C115-HT cells) (Fig 2C), indicating that inhibition of ROCK rescues SERT
functionality. By contrast with TPH2 enzyme, no significant variation in SERT protein level
could be evidenced between Fk-1C115-HT, Rocki-Fk-1C115-HT and uninfected 1C115-HT cells
(Fig 2C). This indicates that the impact of prion infection on SERT activity does not relate to
modulation of SERT synthesis.
Using [3H]-tetrabenazine that selectively binds to the Vesicular Monoamine Transporter
(VMAT), we monitored that antagonizing ROCK activity restored 5-HT storage in Rocki-Fk-
1C115-HT cells with a tetrabenazine binding value that was 2- (Y-27632) to 2.5- (dimethylfasu-
dil) fold increased as compared to Fk-infected 1C115-HT cells (30% of that measured with unin-
fected 1C115-HT cells) (Fig 2D). Restoration of normal serotonergic neuronal functions upon
ROCK inhibition was further supported by a 10- (Y-27632) to 15- (dimethylfasudil) fold
increase of 5-HT content (Fig 2E), decreased levels (30 to 40%) of the 5-hydroxyindolacetic
acid (5-HIAA) degradative product of 5-HT (Fig 2F), and deep reduction (50 to 70%) in the
intracellular content of serotonin-derived oxidized neurotoxins (Fig 2G).
Altogether, these data demonstrate that inhibition of ROCK activity in prion-infected 1C11
cells rescues neuritogenesis and the overall serotonergic-associated functions.
Prion infection of primary neurons triggers synapse disconnection and
neurite degeneration through a ROCK-dependent mechanism
To extend our study to mature neurons, we combined the use of primary cultures of mouse cer-
ebellar granule neurons (CGNs) and of a reconstructed cortico-striatal neuronal network
grown on microfluidic chips [34–36]. CGNs are helpful to probe the effect of prion infection
on the axon and dendrites [37,38]. The reconstructed cortico-striatal network on microfluidic
device offers the possibility to infect cortical neurons in the somato-dendritic side and to moni-
tor the impact of prion infection at distance on synapse connectivity between cortical and stria-
tal neurons.
We showed that infection of CGNs with 22L strain triggered neuronal dysfunction as
inferred by the fragmentation of axon and dendrites by 11 days post-infection (dpi), using
SMI31 and MAP2 as markers of the axon and dendrites, respectively (Fig 3A). Western blot
analyses revealed a 2-fold increase in cofilin phosphorylation level in 22L-infected CGNs vs.
uninfected CGNs (Fig 3B), indicative of an overactivation of ROCK in infected CGNs. Treat-
ment of 22L-infected CGNs with the ROCK inhibitors Y-27632 (100 μM) or dimethylfasudil
(2 μM) at 7 dpi for 4 days exerted a protective effect towards PrPSc-induced neurite degenera-
tion, since ~70 to 90% of treated infected neurons displayed unfragmented dendrites and axon
(Fig 3A). Such protective effect of ROCK inhibitors on axon and dendrites of 22L-infected
CGNs relates to rescued cofilin activity as shown by cofilin phosphorylation level that returned
to basal level upon cell treatment with either Y-27632 or dimethylfasudil (Fig 3B).
With reconstructed cortico-striatal networks, we observed that challenging the cortical
compartment with 22L strain promoted disconnection and retraction of synapses between cor-
tical and striatal neurons by 11 dpi, as inferred by pre-synaptic cortical v-GLUT1 immunos-
taining no longer colocalized with post-synaptic striatal dendrite MAP2 staining (Fig 3C).
ROCK inhibition with Y-27632 (20 μM) or dimethylfasudil (2 μM) applied in the striatal
chamber by 7 dpi for 4 days attenuated PrPSc-induced neuronal disconnection and synapse
retraction by ~100% (Fig 3C).
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Fig 3. Inhibition of ROCK protects primary neuronal cultures from prion-induced synapse disconnection and neurite degradation. (A)
Immunofluorescent labeling of dendrites (anti-MAP2 staining, green) and axons (phospho-NFL200 staining, red) of cerebellar granule neurons (CGNs)
infected with 22L prions for 7 days and then treated 4 days with Y-27623 (100 μM) or dimethylfasudil (2 μM) as compared to uninfected CGNs. Scale bars,
50 μm. Quantification histograms of neurons with fragmented dendrites or axons. (B) Western blot and histogram quantifications for phosphorylated cofilin on
Ser3 in 22L-infected CGNs treated or not with dimethylfasudil or Y-27632 versus uninfected CGNs. (C) Schematic of the experimental procedure with a
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As a whole, our data indicate that prion-induced ROCK activation in mature neurons dis-
rupts neuronal polarity and connectivity. Inhibition of ROCK activity protects neurons from
prion-induced synapse disconnection and dendrite/axon degeneration.
ROCK inhibition promotes strong reduction of PrPSc level by rescuing
TACE α-secretase-mediated PrPC α-cleavage in a PDK1-dependent
manner
We next investigated whether PrPSc accumulation in prion-infected cells would depend on
ROCK overactivity. Inhibition of ROCK with dimethylfasudil (2 μM) or Y-27632 (100 μM)
decreased the amount of proteinase K-resistant PrPSc (PrPres) by 80 to 90% in either Rocki-Fk-
1C115-HT cells (Fig 4A) or primary cultures of 22L-infected CGNs (Fig 4B). These observations
introduce ROCK overactivation as a novel pathogenic event contributing to the conversion of
PrPC into PrPSc.
We recently reported that accumulation of PrPSc in prion diseases relates to internalization
of TACE α-secretase in caveolin-1 (Cav-1)-enriched microvesicles caused by PDK1 overactiva-
tion, which cancels PrPC neuroprotective α-cleavage by TACE [24]. The question was thus to
assess whether the reduction of PrPSc level measured upon ROCK inhibition would depend on
a control of the PDK1-TACE module by ROCK. Inhibition of ROCK with Y-27632 (100 μM,
1h) promoted translocation of TACE back to the cell surface of Fk-1C115-HT cells (Fig 4C) and
22L-infected CGNs (S2A Fig). Detergent-free sucrose gradient membrane fractionation of cell
extracts followed by western blotting further revealed that TACE no longer co-distributed with
Cav-1 in Fk-1C115-HT cells exposed to Y-27632, but was found together with the focal adhesion
kinase (FAK) at the plasma membrane of infected 1C115-HT cells as observed with uninfected
1C115-HT cells (Fig 4D). With Rocki-Fk-1C115-HT cells differentiated for 4 days in the presence
of Y-27632, TACE was at the plasma membrane of both the cell body and neurites with a dis-
tribution pattern highly comparable to that of uninfected 1C115-HT cells (Fig 4E).
Redirection of TACE to the cell surface of infected cells upon ROCK inhibition rescued
TACE-mediated α-cleavage of PrP between residues 111/112 and generated an N-terminal
truncated fragment (that is, membrane C1) (Figs 4F and S2B) that does not convert into PrPSc
[39]. In Fk-1C115-HT cells and 22L-CGNs, the ratio between PrP C1 fragment and full length
PrP (native) was reduced by approximately 75% as compared to that of uninfected cells (Figs
4F and S2B), thus accounting for conversion of PrPC into PrPSc. In infected cells treated with
Y-27632 (100 μM) for 6 h the C1/native ratio was ~2- to 3-fold increased compared to
untreated infected cells (Figs 4F and S2B), indicative of restored PrPC α-cleavage. Such an
increase in C1/native ratio in the presence of the ROCK inhibitor depends on TACE activity,
since inhibition of TACE with TAPI-2 (100 μM, 1h) counteracted the effects of Y-27632 on
PrP neuroprotective cleavage (Figs 4F and S2B).
Finally, while PDK1 activity was 2- to 3-fold increased in Fk-infected 1C115-HT cells (Fig
4G) and 22L-infected CGNs (S2C Fig), ROCK inhibition in Fk-1C115-HT cells or 22L-CGNs
with Y-27632 (100μM, 1h) reduced PDK1 activity by ~50 to 70% to basal level measured with
uninfected cells (Figs 4G and S2C). Of note, bombardment of Fk-infected 1C115-HT cells with
reconstructed cortico-striatal neuronal network on microfluidic devices and immunofluorescent labelings. Cortical neurons of a 10 days-in-vitro (DIV)-aged
cortico-striatal network were infected with 22L prions for 7 days. Striatal neurons were then treated with Y-27632 (20 μM) or dimethylfasudil (2 μM) for 4 days.
Dendrites (anti-MAP2 staining, blue) of striatal neurons and synapses (anti-v-GLUT1 staining, red) and axons (anti-α-tubulin, green) of cortical neurons were
labeled with specific antibodies. Close proximity of blue (striatal dendrites) and red (v-GLUT1 cortical presynaptic terminal) signals indicates cortico-striatal
connectivity. Scale bars, 50 μm. Each point corresponds to the mean of number synapses per μm dendrite determined from the analysis of ten pictures. n = 6
for each condition. For each group, individual mean values and mean (line) are shown. # P < 0.05 versus uninfected cells. ## P < 0.05 versus non treated
infected cells.
doi:10.1371/journal.ppat.1005073.g003
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Fig 4. ROCK inhibition lowers PrPSc level by rescuing TACE α-secretase neuroprotective activity towards PrPC in a PDK1-dependent manner. (A,
B) Amount of PrPSc in Rocki-Fk-1C115-HT cells differentiated into serotonergic neuronal cells for 4 days (4d) in the presence of Y-27632 (100 μM) or 22L-
infected CGNs exposed for 6 h to Y-27632 (100 μM), as shown by western blotting (left) and quantified by ELISA (right). n = 10 for each condition. (C)
Immunofluorescent labeling of TACE at the surface of Fk-infected 1C115-HT cells treated or not with the ROCK inhibitor (Y-27632, 100 μM) for 1 h. Scale bar,
50 μm. (D) Immunoblot analysis of sucrose gradient fractions of membranes of Fk-infected 1C115-HT cells treated or not with Y-27632 (100 μM, 1h) versus
ROCKOveractivity in Prion Diseases
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tungsten microprojectiles coated with ROCK-I antibodies [24,40] restored basal PDK1 activity,
while tungsten microprojectiles coated with ROCK-II antibodies triggered less reduction of
PDK1 activity (~45%) (Fig 4G), indicating that ROCK-I overactivity within an infectious con-
text mainly contributes to the overactivation of PDK1. The rise in PDK1 activity was also coun-
teracted in Rocki-Fk-1C115-HT cells differentiated for 4 days in the presence of Y-27632 (Fig
4G), further demonstrating that the control of PDK1 activity by ROCK-I occurs in polarized
cells as well as in non-polarized Fk-1C115-HT cells.
These overall data firmly establish that ROCK act as upstream positive regulators of PDK1
activity and contribute to prion-induced neurodegeneration by favoring the production of PrPSc.
ROCK-I interacts with PDK1 and promotes PDK1 phosphorylation
The acute regulation of PDK1 activity relies on a complex interplay between PDK1 phosphory-
lation, subcellular localization, binding of regulators and conformational changes (for review
see [41] and references therein). To investigate how ROCK-I regulates PDK1 activity, we
designed a first set of experiments centered on the interaction between ROCK-I and PDK1. In
uninfected 1C115-HT cells, ROCK-I immunoprecipitation followed by PDK1 western blotting
revealed that ROCK-I interacts with PDK1 (Fig 5A). In Fk-infected 1C115-HT cells, the fraction
of PDK1 interacting with ROCK-I was ~2-fold increased compared to uninfected cells (Fig
5A). Of note, the level of ROCK-I did not vary between uninfected 1C115-HT and Fk-1C115-HT
cells (Fig 5A). The rise in ROCK activity induced by PrPSc thus increases the number of PDK1
molecules recruited by ROCK-I. Exposure of uninfected 1C115-HT or Fk-1C115-HT cells to Y-
27632 (100 μM) for 1h dissociated the ROCK-I / PDK1 complex by ~70% and ~90%, respec-
tively (Fig 5A), further indicating that the ROCK-I-kinase activity is necessary for its associa-
tion with PDK1.
To next probe whether ROCK-I phosphorylates PDK1, cells treated or not with Y-27632
(100 μM, 1h) were metabolically labeled for 60 min with [32P]-orthophosphate (8.81 μCi.mL−1)
and [32P]-labeled PDK1 level was quantified after PDK1 immunoprecipitation and western
blotting. In uninfected 1C115-HT cells, PDK1 phosphorylation level was reduced by ~70% in the
presence of Y-27632 (Fig 5B), indicating that ROCK-I does phosphorylate PDK1 under physio-
logical conditions. From a mechanistic point of view, autophosphorylation of PDK1 Ser241 is
critical but not sufficient to induce PDK1 full activity [42]. Depending on the cell type and sig-
naling pathways converging on PDK1, additional phosphorylations on Ser, Thr and Tyr resi-
dues located in the kinase domain, the pleckstrin-homology (PH) domain and in the linker
between the kinase and PH domains have already been shown to enhance PDK1 activity in a
more or less cooperative manner [41,43]. Here, we provide evidence that PDK1 autophosphory-
lation at Ser241 precedes PDK1 phosphorylation by ROCK-I on yet-to-be identified residues.
Indeed, site-directed mutagenesis of PDK1 Ser241 into Ala to mimic a constitutive dephosphor-
ylation (S241A) state decreased by ~90% the incorporation of 32P on the S241A PDK1 mutant
when transfected into 1C115-HT cells (Fig 5B). Besides, immunoprecipitation experiments
uninfected 1C115-HT to assess TACE displacement from the plasmamembrane (FAK-enriched fractions) to caveolin-1-enriched vesicles. FAK = Focal
Adhesion Kinase. Cav-1 = caveolin-1. (E) Immunofluorescent labeling of TACE at the surface of Rocki-Fk-1C115-HT differentiated for 4 days in the presence
of Y-27632 (100 μM) versus uninfected 1C115-HT cells. Scale bar, 50 μm. (F) Western blot analysis (top) of the C1 fragment of PrP (C1) and full-length PrP
(native) in Fk-infected 1C115-HT cells treated or not with Y-27632 (100 μM) or a combination of Y-27632 (100 μM) and TAPI-2 (100 μM) for 6 h versus
uninfected cells and the ratio (bottom) of C1/native full-length PrP. n = 5 for each condition. (G) PDK1 activity in Fk-infected 1C115-HT cells treated or not with
Y-27632 (100 μM, 1 h), in Fk-infected 1C115-HT bombarded with tungsten microprojectiles coated with ROCK-I or ROCK-II antibodies or both, or in Rocki-Fk-
1C115-HT cells differentiated for 4 days in the presence of Y-27632 (100 μM) versus uninfected 1C115-HT cells. n = 5 for each condition. Values are the
mean ± s.e.m. for all experiments. * P <0.01 versus uninfected cells. ** P <0.01 versus non-treated infected cells. # P <0.05 versus uninfected cells. ## P
<0.05 versus non treated infected cells. ### P <0.05 versus infected cells treated with Y-27632.
doi:10.1371/journal.ppat.1005073.g004
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showed that ROCK-I did not complex with the S241A PDK1 mutant (Fig 5A). These data
establish that autophosphorylation of PDK1 Ser241 is essential for PDK1 interaction with
ROCK and further phosphorylation by ROCK.
We next examined the phosphorylation status of PDK1 within an infectious context. The
level of phosphorylated PDK1 was 2-fold higher in Fk-infected 1C115-HT cells than in unin-
fected cells (Fig 5B). Such increase in PDK1 phosphorylation level was cancelled upon treat-
ment of Fk-1C115-HT cells with Y-27632 (100 μM) for 1h or in Rocki-Fk-1C115-HT cells left to
differentiate for 4 days in the presence of Y-27632 (Fig 5B), indicating that prion-induced
ROCK overactivity enhances PDK1 phosphorylation level and that ROCK-induced phosphor-
ylation of PDK1 is independent on the acquisition of neuronal polarity.
As a whole, our data reveal that ROCK-I constitutively complexes with and phosphorylates
PDK1 in uninfected cells. Autophosphorylation of PDK1 at Ser241 is a prerequisite for PDK1
interaction with ROCK-I and further phosphorylation by ROCK-I. In prion-infected cells,
ROCK overactivation augments by 2-fold the pool of PDK1 molecules interacting with and
phosphorylated by ROCK-I, which thus enhances PDK1 activity.
Antagonizing ROCK activity improves disease in mouse models of prion
infection
In adult C57BL/6J mice inoculated with the mouse-adapted scrapie strain 22L via the intracere-
bellar route [44] and sacrificed at 130 days post infection (dpi) just before the symptomatic
phase, a marked increase in phosphorylated cofilin immunostaining that matched with PrPSc
deposition was observed in the brain of prion-infected mice in both the cerebellar cortex
(CBCX) and deep cerebellar nuclei (DCN) compared to uninfected animals (SHAM) (Fig 6A
and 6B). Western-blot analyses of cerebellum extracts indicated a ~2 to 3-fold increased level
of phosphorylated cofilin in 22L-infected vs. SHAMmice (Fig 6C).
Fig 5. ROCK-I interacts with PDK1 and phosphorylates PDK1. (A) Immunoprecipitation of ROCK-I and immunoblotting of PDK1 in uninfected 1C115-HT
or Fk-1C115-HT treated or not with Y-27632 (100 μM, 1h) as well as in 1C115-HT transfected with S241A PDK1mutant. (B) Cell 32P metabolic labeling
followed by PDK1 immunoprecipitation and western blotting for PDK1 phosphorylation level in uninfected 1C115-HT or Fk-1C115-HT treated or not with Y-
27632 (100 μM, 1h) as well as in 1C115-HT transfected with S241A PDK1 mutant. Values are the mean ± s.e.m. # P < 0.05 versus non treated uninfected
cells. ## P < 0.05 versus non treated infected cells.
doi:10.1371/journal.ppat.1005073.g005
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Fig 6. ROCK inhibition with Y-27632 attenuates prion disease in mice. (A) Cerebellar immunoperoxidase staining to visualize PrPSc deposition in the
cerebellar cortex (CBCX) and deep cerebellar nuclei (DCN) of 22L-infected mice, Scale bars, 100 μm. (B) Immunoperoxidase staining to visualize
phosphorylated cofilin on Ser3 in CBCX and DCN of mock-inoculated (SHAM) and 22L-infected mice. Scale bars, 100 μm. (C) Western blot and histogram
quantifications for phosphorylated cofilin on Ser3 in 22L-infected mice infused or not with Y-27632 versus SHAMmice. n = 4 in triplicate. (D) Survival curves
of SHAM and 22L-inoculated mice via the intracerebellar route (i.c.b.) infused or not with the ROCK inhibitor Y-27632 by intraperitoneal injection (i.p.) starting
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Because increased cofilin phosphorylation in the brain of prion-infected mice argues for
ROCK overactivity in vivo, we next wondered whether inhibition of ROCK would attenuate
prion disease. Y-27632, known to easily cross the Blood Brain Barrier [30], was first chronically
injected intraperitoneally (i.p.) in adult C57BL/6J mice starting 130 days after infection and
before the onset of clinical signs (140 days). We showed that Y-27632 treatment delayed mor-
tality in 22L-infected mice as compared to untreated mice (181.4 +/- 4.7 days versus 166.0 +/-
1.8 days, n = 10, P< 0.0001, Fig 6D) with no overt sign of Y-27632 toxicity. Reduction of phos-
phorylated cofilin level in post-mortem cerebellum extracts from 22L-infected mice upon Y-
27632 treatment indicated ROCK inhibition in brain (Fig 6C). Y-27632 infusion also decreased
prion infection-induced impairments in motor function (Fig 6E). While in 22L-infected mice
the mean static rod score dropped to 10 by 145 days, in Y-27632-treated infected mice, the
mean static rod score never dropped below 10. In SHAMmice, motor coordination was non-
sensitive to Y-27632 treatment.
We further showed that the beneficial effect of ROCK inhibition against prion disease corre-
lated with decreased levels of PrPSc. Post-mortem quantifications of proteinase K-resistant PrP
revealed a ~30% reduction in PrPres level in the brains of 22L-infected mice infused with Y-
27632 compared to untreated infected animals (Fig 6F), indicative of PDK1 down-regulation
(Fig 6G), TACE relocation to the plasma membrane (Fig 6H) and rescue of PrPC α-cleavage by
TACE upon ROCK inhibition in vivo (Fig 6I). Accordingly, while PDK1 activity was ~3-fold
enhanced in the brain of 22L-infected mice compared to SHAMmice, PDK1 activity decreased
by ~50% in prion-infected mice treated with Y-27632 vs. untreated infected mice (Fig 6G). As
for prion-infected 1C115-HT cells and CGNs, reduction of PDK1 activity in the brain of 22L-
infected mice infused with Y-27632 originated from disruption of the ROCK-PDK1 complex
(Fig 6J).
Finally, C57Bl/6J mice inoculated with 22L prions were also intraperitonealy injected with
dimethylfasudil following the same procedure as for Y-27632. ROCK inhibition with dimethyl-
fasudil prolonged the survival time of infected mice compared to untreated mice (174.8 +/- 4.3
days versus 166.0 +/- 1.8 days, n = 10, P< 0.0001, S3A Fig), reduced phospho-cofilin level in
the cerebellum (S3B Fig), counteracted prion-induced motor deficits (S3C Fig), decreased
brain PrPSc level by 30% (S3D Fig), as a consequence of dissociation of the ROCK/PDK1 com-
plex (S3E Fig) and reduction of PDK1 activity (S3F Fig).
Altogether, these data demonstrate that targeting ROCK activity mitigates prion diseases.
Discussion
Our findings indicate that PrPSc-induced ROCK overactivity contributes to neuronal cell
demise at two levels: through (i) alterations of neuronal polarity, connectivity and neurotrans-
mitter-associated functions and (ii) amplification of the production of neurotoxic PrPSc.
ROCK inhibition not only restores neuritogenesis and neurotransmitter-associated functions,
at 130 days after infection (5 mg per kg body weight per day; 0.25 μl h-1). n = 10 mice per group. (E) Static rod test between 130 and 160 days after infection
in 22L-infected mice treated with Y-27632. n = 10 mice per group. (F) Left, Western-blot for proteinase K-resistant PrPSc in brain extracts from SHAM and
22L-infected mice infused or not with Y-27632. Right, post-mortem quantification of proteinase K-resistant PrPSc in brains of 22L-infected mice treated or not
with Y-27632. n = 10 for each condition. (G) PDK1 activity in cerebellar extracts of 22L-infected mice treated or not with Y-27632 versus SHAMmice. n = 9 for
each condition. (H) Immunoblot analysis of sucrose gradient fractions of cerebellar extracts of SHAMmice and 22L-infected mice infused or not with Y-27632
to assess TACE displacement from the plasmamembrane (FAK-enriched fractions) to caveolin-1-enriched vesicles in vivo. (I) Western blot analysis (top) of
the C1 fragment of PrP (C1) and full-length PrP (native) in cerebellar extracts from SHAM and 22L-infected mice infused or not with Y-27632 and the ratio
(bottom) of C1/native full-length PrP. Note that mouse infection with 22L strain is associated with decreased PrP α-cleavage at the expense of PrP β-
cleavage that generates C2 fragment [68, 69]. n = 5 for each condition. (J) ROCK immunoprecipitation followed by PDK1 western blotting in cerebellar
extracts of 22L-infected mice treated or not with Y-27632 versus SHAMmice. n = 9 for each condition. Values are the mean ± s.e.m. * P < 0.01 versus SHAM
mice. ** P < 0.01 versus 22L-infected mice. # P < 0.05 versus SHAMmice ## P < 0.05 versus 22L-infected mice.
doi:10.1371/journal.ppat.1005073.g006
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but also reduces the production of PrPSc, which thereby lengthens the survival of prion-
infected mice (Fig 7).
The rise in ROCK activity in prion-infected cells originates from loss of PrPC regulatory
function towards the RhoA-ROCK-LIMK-cofilin pathway [15] upon PrPC conversion into
PrPSc. Downstream modifications of F-actin structure and dynamics impair the onset of neur-
ites by differentiating 1C11 neuronal stem cells, disrupt synapse connectivity and provoke
Fig 7. Schematic representation of ROCK dysregulation in prion-infected cells and incidence of ROCK overactivity on neuritogenesis and PrPSc
production. Prion infection causes the overstimulation of ROCK. Overactivated ROCK alters neuronal polarity by disrupting the dynamics of F-actin
cytoskeleton through the LIM kinases/cofilin signaling pathway. Overactivated ROCK also amplifies PrPSc production by acting on the PDK1/TACE signaling
module. Prion infection increases the pool of PDK1 molecules interacting with ROCK and phosphorylated by ROCK, at the root of increased PDK1 activity.
ROCK-induced PDK1 overactivation promotes the internalization of TACE α-secretase in caveolin-1-enriched vesicles, which cancels TACE neuroprotective
α-cleavage of PrPC at the plasmamembrane of prion-infected cells. The accumulation of PrPSc fuels the activation of ROCK, the formation of ROCK/PDK1
complex and the increase in PDK1 activity and thereby sustains a vicious circle that contributes to prion disease progression. The inhibition of ROCK with Y-
27632 or dimethylfasudil (i) rescues F-actin plasticity necessary for neuritogenesis, synapse connectivity and the integrity of axon/dendrites, and (ii) disrupts
the ROCK/PDK1 complex, which lowers PDK1 activity and allows TACE to target back to the plasmamembrane. Relocated TACE upon ROCK inhibition
recovers its cleavage activity towards PrPC and attenuates PrPC conversion into PrPSc. ROCK emerges as potential therapeutic target to combat prion
diseases.
doi:10.1371/journal.ppat.1005073.g007
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neurite degradation in primary neuronal cultures. Our data provide evidence that PrPSc-
induced ROCK overactivation exerts a dominant negative effect on neuronal polarity since the
sole inhibition of ROCK is sufficient to restore neurite sprouting and protect mature neurons
from prion-induced axon and dendrite alterations. The beneficial effect afforded by ROCK
inhibition on neuritogenesis and neuronal architecture relates to rescued cofilin-mediated sev-
ering of F-actin and improved actin dynamics in prion-infected cells. This however does not
exclude that modulation of other signaling effectors known to regulate neuronal outgrowth
downstream from ROCK, such as profilin IIa [45], also partakes to restoration of neuronal
morphology upon ROCK inhibition.
Our data further show that prion infection of 1C11 neuronal stem cells alters the coupling
between cell morphogenesis and the acquisition of neuronal functions. Inhibition of ROCK
not only restores neuritogenesis but also rescues the overall neurotransmitter-associated func-
tions. How the inhibition of ROCK permits to restore neuronal functions has however not
been deciphered. Neuritogenesis and the onset of neurotransmitter-functions are interconnec-
ted events since the actin cytoskeleton directs the transport of specific mRNAs and proteins
[46–48] and acts as a scaffold that orchestrates local protein translation [47,49,50] within
axons and dendrites. Of note, all the mRNAs coding for neuronal functions are expressed in
1C11 cells at the stem cell stage but are dormant [51]. Prion infection does not impact on the
expression level of these mRNAs (S4 Fig). The drastic reduction of Tryptophan Hydroxylase-2
(TPH2) expression measured in prion-infected 1C115-HT neurons might thus originate from
abnormal trafficking of TPH2 mRNA and/or compromised translation. Interestingly, overpho-
sphorylation of the translation initiation factor eiF2α, subsequent decrease of its activity and
repression of protein synthesis have been shown to contribute to the progression of prion dis-
eases [52]. Whether rescue of TPH2 protein synthesis upon ROCK inhibition relates to a resto-
ration of eiF2α activity needs further investigation. By contrast with TPH2, the loss of
Serotonin Transporter (SERT) functionality within an infectious context does not originate
from reduced SERT expression, indicating that PrPSc interferes with the translation of specific
mRNAs. Rescue of SERT activity upon ROCK inhibition may alternatively be linked to reduc-
tion of the intracellular concentration of serotonin-oxidized neurotoxins that are assumed to
poison the SERT protein [23], corroborating the antioxidant effect of ROCK inhibition [53,54].
A major output of this work is the reduction, upon ROCK inhibition, of PrPSc level in
prion-infected cells or in the brain of 22L-infected mice. Such reduction in brain PrPSc likely
accounts for improved motor function and increased survival of prion-infected animals treated
with the ROCK inhibitor. In this work, we decipher how ROCK contributes to the conversion
of PrPC into PrPSc. Under physiological conditions ROCK-I acts as positive regulator of PDK1
activity. ROCK-I interacts with and phosphorylates PDK1. At a mechanistic level, prior autop-
hosphorylation of Ser241 in the kinase domain of PDK1 is necessary to ROCK-I interaction
and subsequent PDK1 phosphorylation by ROCK-I, suggesting that PDK1 phosphorylation at
Ser241 induces conformational changes unmasking binding site(s) for ROCK-I and/or phos-
phorylatable residues by ROCK-I. Additional phosphorylation of PDK1 by ROCK-I improves
the stability of the ROCK-I/PDK1 complex. In prion-infected cells, the rise in ROCK activity
increases the pool of PDK1 molecules interacting with and phosphorylated by ROCK-I at the
root of the PDK1 activity overboost within an infectious context (Fig 7). Such ROCK-depen-
dent overstimulation of PDK1 activity in turn cancels plasma membrane TACE neuroprotec-
tive α-cleavage of PrPC and thereby favors the production of PrPSc [24]. We previously showed
that a rise in Src kinases-PI3K signaling in prion-infected cells also enhanced PDK1 activity
[24], likely as the result of an accelerated PDK1 docking to the plasma membrane by phospha-
tidylinositol 3,4,5-trisphosphate and subsequent phosphorylation by Src kinases [41,43]. Inhi-
bition of ROCK in prion-infected cells is however sufficient to decrease PDK1 activity up to its
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basal level as does the sole inhibition of Src kinases or PI3K [24], thus suggesting that the Src
kinases-PI3K and ROCK pathways are both required for overstimulation of PDK1 activity
within an infectious context.
Inhibition of ROCK has been shown to exert beneficial effects towards other amyloid-based
neurodegenerative diseases such as Alzheimer’s (AD) [55] or Parkinson’s diseases [56,57]. In
mouse models with AD-like pathology, decreased levels of neurotoxic amyloid Aβ peptides
upon ROCK inhibition have been attributed to disruption of amyloidogenic processing of the
amyloid precursor protein APP by the β-secretase BACE [58]. In brain samples from AD sub-
jects as well as in three mouse models with AD-like pathology, PDK1 overactivity was also
shown to contribute to the accumulation of Aβ40/42 peptides and the progression of AD by
cancelling the non-amyloidogenic processing of APP by TACE [24]. By showing that ROCK
overactivation is a novel pathogenic event in TSEs and that ROCK control PDK1 activity, we
propose that the beneficial effect afforded by ROCK inhibition against AD also reflects down-
regulation of PDK1 activity and rescue of TACE α-secretase activity towards APP. In any case,
in the absence of effective medicine, further understanding the functional interplay between
ROCK and PDK1 may help to design novel therapeutic strategies for amyloid-based neurode-
generative disorders.
Materials and Methods
Antibodies
The rat monoclonal CD9 antibody was a kind gift from E. Rubinstein (Inserm, Villejuif,
France) [59]. The mouse monoclonal SAF32 PrP antibody was from SPI-Bio (Montigny Le
Bretoneux, France). The mouse monoclonal ICSM33 PrP antibody was from D-Gen Limited
(London, UK). The mouse monoclonal anti-CD29 (β1 integrin) antibody was from BD Trans-
duction Laboratories (Lexington, KY, USA). The rat monoclonal 9EG7 anti-activated β1 integ-
rin antibody [60] was from Pharmingen (San Diego, CA, USA). The mouse monoclonal
antibody to α-tubulin was from Novus Biologicals (Littleton, CO, USA). The rabbit polyclonal
antibody targeting phospho-LIMK1/2 (pThr505 and pThr508) was from AbCam (Cambridge,
MA, USA). Rabbit polyclonal antibodies toward LIMK1 and cofilin were from Cell Signaling
(Beverly, MA, USA). The rabbit polyclonal anti-phospho-Ser3-cofilin antibody was from Santa
Cruz Biotechnology (SantaCruz, CA, USA). The rabbit polyclonal anti-TPH2 antibody was
from Genway (San Diego, CA, USA). The rabbit polyclonal anti-SERT antibody was from Che-
micon (Temecula, CA, USA). The rabbit polyclonal antibody to MAP2, the mouse polyclonal
antibody to phospho-NFL200 (SMI31) and the guinea pig polyclonal anti-v-GLUT1 antibody
were from EMDMillipore (Darmstadt, Germany). Rabbit polyclonal antibody to TACE was
purchased from QED Bioscience (San Diego, CA, USA). The rabbit polyclonal antibodies to
caveolin-1 (Cav-1) and focal adhesion kinase (FAK) were from Transduction laboratories
(Lexington, KY, USA) and Santa Cruz Biotechnology (SantaCruz, CA, USA), respectively. The
rabbit monoclonal ROCK-I and polyclonal ROCK-II and PDK1 antibodies were from Cell Sig-
naling (Beverly, MA, USA). When nonspecified, primary antibodies were used at 0.5 μg ml−1
for western blot experiments and at 5 μg ml−1 for immunofluorescence experiments.
Ethics statement
Adult C57Bl/6J mice were bred and underwent experiments in level-3 biological risk contain-
ment, respecting European guidelines for the care and ethical use of laboratory animals (Direc-
tive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the
protection of animals used for scientific purposes). Mice received intracerebral inoculation of
the cerebellotropic 22L scrapie strain [44] (CNRS Strasbourg, France). All animal procedures
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were approved by the Comité Régional d’Ethique en Matière d’Expérimentation Animale de
Strasbourg (France; CEEA35 ref AL/01/01/01/13) and the Animal Care and Use Committee at
Basel University (Switzerland).
Chronic intraperitoneal injection of Y-27632 or dimethylfasudil into mice
Mice were fasted overnight but allowed water ad libitum before the experiment. They were
then anesthetized with isoflurane inhalation, and a midline incision was performed to insert
into the peritoneum the polyethylene catheter of an osmotic pump (Alzet, Cupertino, CA,
USA). Y-27632, dimethylfasudil or vehicle (1% DMSO in sterile normal saline buffer) was
administered at a flow rate of 0.25 μL h-1, which corresponded to 100 μg per mouse per day (5
mg kg−1 per day for Y-27632 and 3 mg kg−1 per day for dimethylfasudil). Pumps were replaced
every 4 weeks.
Behavioral testing
Motor function in 22L-infected mice was assessed by the static rod test [61].
Cell culture and prion infection
1C11 cells chronically infected or not by the mouse-adapted 22L or Fukuoka (Fk) strains [23]
were grown and induced to differentiate along the serotonergic (1C115-HT) pathway [22]. Pri-
mary CGNs were isolated from dissociated cerebella of 4- to 5-day-old C57Bl/6J mice and
infected by the 22L strain [37,38].
Cortico-striatal network with microfluidic chips
“Axon diode”microfluidic chips were designed and fabricated as previously described [34].
Briefly, Polydimethylsiloxane (Sylgard 184, PDMS, Dow Corning, Midland, MI, USA) was
mixed with a curing agent (9:1 ratio) and degassed under vacuum. The resulting preparation
was poured onto a polyester resin replicate and reticulated at 70°C for 2 h. The elastomeric
polymer print was detached and two reservoirs were punched for each macro-channel. The
resulting piece was cleaned with isopropanol and dried. The polymer print and a glass cover
slip were treated for 200 sec in an air plasma generator (98% power, 0.6 mBar, Diener Elec-
tronic, Ebhausen, Germany) and bonded together. The chips were then coated with a solution
of poly-D-lysine (10 μg ml-1, Sigma; St. Louis, MO, USA) overnight and washed with PBS
before cell seeding.
Embryonic cortical and striatal neurons were obtained and cultured as previously described
[34,35]. Briefly, cortices and ganglionic eminences (striatal neurons) were micro-dissected
from E14 embryos of C57Bl/6J pregnant mice and digested with papaïn (20 U ml-1 in DMEM,
Sigma Aldrich). Cortices and Striata were mechanically dissociated and neurons were collected
by centrifugation. Cells were then re-suspended for plating in DMEM-Glutamax I (Life Tech-
nologies) supplemented with penicillin and streptomycin (Life Technologies), N2 and B27 sup-
plements (Life Technologies) and 5% FBS (PAA). ~105 cortical neurons and ~2.4 x 104 striatal
neurons were seeded respectively in cortical and striatal compartments, as described before
[34]. Microfluidic chips were incubated at 37°C in humid atmosphere with 5% CO2. The cul-
ture medium was renewed every 7 days. Upon time of interest, cells were fixed using a 4% PFA,
4% sucrose solution diluted in PBS and further processed by immuno-cytochemistry with anti
MAP2, α- tubulin and v-GLUT1 antibodies.
ROCKOveractivity in Prion Diseases
PLOS Pathogens | DOI:10.1371/journal.ppat.1005073 August 4, 2015 18 / 25
Immunofluorescent labeling and F-actin visualization
Immunofluorescent labeling of PrPC, PrPSc, β1 integrins, phospho-LIMK1/2, phospho-cofilin,
TACE, MAP2, phospho-NFL200, and v-Glut1 was performed using standard protocols as
reported in [15,37]. F-actin was stained using TRITC-phalloidin (Sigma-Aldrich, St. Louis,
MO, USA) as in [15]. Labelings were analyzed using a Leica DMI6000 B microscope (Wetzlar,
Germany) and subjected to image analysis with AQUA software [62].
Cell extract preparation, PNGase assay and western blot analyses
Cells were washed in PBS/Ca2+/Mg2+ and incubated for 30 min at 4°C in lysis buffer (50 mM
Tris-HCl pH 7.4, 150 mMNaCl, 5 mM EDTA, 1% Triton X-100, 1 mMNa3VO4 and protease
inhibitors (Roche)). After centrifugation of the lysate (14,000g, 15 min), the protein concentra-
tion in the supernatant was measured with the bicinchoninic acid method (Pierce, Rockford,
IL, USA). For the PNGase assay, protein extracts were incubated with 500 U N-glycosidase F
(PNGase, New England Biolabs, Ipswich, MA, USA) for 1 h at room temperature. Solubilized
proteins (20 μg) were resolved by 10% SDS-PAGE. After transfer, blocked membranes were
incubated with SAF61 primary antibody. Bound antibodies were revealed by enhanced chemi-
luminescence detection (ECL, Amersham Pharmacia Biotech, Piscataway, NJ, USA). To
standardize the results, membranes were rehybridized with an anti-α-tubulin antibody. The
ratio between the truncated form of PrP (C1 fragment) and full-length PrP (Native) was
evaluated by densitometric analyses using ImageQuant TL software (GE Healthcare, Little
Chalfont, UK).
Quantification of tryptophan hydroxylase activity
Determination of enzymatic functions was conducted on uninfected 1C115-HT cells, Fk-
infected 1C115-HT cells and Rocki-Fk-1C115-HT cells. After two washings with cold PBS, cells
were scraped and collected down by centrifugation (10,000g, 3 min, 4°C). Tryptophan hydrox-
ylase (TPH) activity was measured radioenzymatically as in [23]. Briefly, cell extracts were
incubated for 30 min at 37°C in an assay mixture containing 200 mMNa acetate, pH 6.1, 1
mM ferrous sulfate, 2 mM 6-methyl-H4-pterin, 40 mM 2-mercaptoethanol, 20 mMNa phos-
phate and 100 μM [3H]-L-tryptophan. TPH activity was determined by quantifying the pro-
duction of [3H]2O in a liquid scintillation counter and expressed as pmol/30 min/mg of cell
protein extract.
Determination of 5-HT, 5-HIAA and 5-HT oxidized products
The contents in 5-HT and related metabolites were measured by HPLC combined to electro-
chemical (EC) detection as described in [23].
Radioligand binding experiments
The presence of vesicular monoamine transporter (VMAT) sites was assessed through [3H]-
tetrabenazine binding as in [23]. [3H]-paroxetine binding to functional 5-HT transporter
(SERT) was carried out as in [33].
Phospho-Ser3-cofilin level and PrPSc deposition in the brains of prion-
infected mice
Prion-infected (n = 3) and control uninfected (n = 6) mice were anaesthetized with ketamine
(125 mg kg-1) and xylazine (17 mg kg-1) and perfused via cardiac aorta with 4% paraformalde-
hyde at 130 days after infection. The cerebellum was removed and cryoprotected in sucrose
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30% before freezing in isopentane at -80°C. Transverse cryostat sections (30 μm-thick) were
cut and submitted floating to classical immuno-peroxidase staining of PrPSc and phosphory-
lated cofilin using SAF32 (1 μg ml−1) and anti-phospho-Ser3-cofilin (2 μg ml−1; Santa Cruz,
CA, USA) antibodies, respectively. The specificity of PrPSc immunodetection was achieved by
denaturing the PrPC by incubation of the sections in proteinase K (10 μg ml−1) for 10 min at
37°C and subsequently in 3.4 M guanidine thiocyanate for 15 min. The PrP- and phospho-
Ser3-cofilin-bound antibodies were visualized using biotinylated anti-mouse or anti-rabbit
immunoglobulins (SouthernBiotech, Birmingham, AL, USA), respectively, and the Vectastain
Elite kit (Vector Labs, Burlingame, CA, USA).
ROCK inhibition
ROCK activity was inhibited with dimethylfasudil (Calbiochem, San Diego, CA, USA) or Y-
27632 (Tocris Bioscience, Ellisville, MO, USA).
PrPres quantification
The amount of proteinase K–resistant PrP (PrPres) in infected cell lysates or brain extracts of
22L-infected mice infused or not with Y-27632 or dimethylfasudil were determined using a
PrP-specific sandwich ELISA [24,63] after proteinase K digestion (10 μg ml−1) for 1 h at 37°C.
Sucrose gradient fractionation of cell membranes
TACE was detected by western blot analysis after sucrose gradient membrane fractionation of
cell or cerebellar extracts performed under detergent-free conditions to isolate low buoyant
fractions enriched in caveolin-1 proteins [24,64].
Measurement of PDK1 activity
PDK1 activity was measured in cell lysates or cerebellar extracts using a fluorescently labeled
PDK1 substrate (5FAM-ARKRERTYSFGHHA-COOH, Caliper Life Sciences, Hanover, MD,
USA) as reported in [24,64]. The relative amounts of substrate peptide and product phospho-
peptide were determined using a Caliper EZ-reader (Caliper Life Sciences, Hanover, MD,
USA).
ROCK immunosequestration
ROCK-I or ROCK-II immunosequestration was performed by cell bombardment with tung-
sten microprojectiles coated with antibody to ROCK-I or ROCK-II [24,64].
ROCK-I immunoprecipitation
ROCK-I immunoprecipitation was performed according to standard protocols by using pro-
tein A-Sepharose beads (Amersham Pharmacia Biotech, Picataway, NJ, USA) coupled to anti-
ROCK-I antibody and 100 μg of cell lysates or cerebellar extracts. Immunoprecipitates were
analyzed by western blotting using anti-ROCK-I and anti-PDK1 antibodies.
Cell metabolic labeling with [32P]-orthophosphate
[32P]-orthophosphate labeling was performed as in [65]. Briefly, the cell culture medium was
removed and cells were thoroughly washed with phosphate-free DMEM to eliminate any resid-
ual phosphate-containing medium. [32P]-orthophosphate (40.7 Gbq mmol-1, GE Healthcare,
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Little Chalfont, UK) was added to the cell culture at a final concentration of 18.5 Mbq ml-1.
After 2 h, the labeling medium was removed and the cells were lyzed after extensive washing.
Cell transfection of S241A PDK1 mutant
Endogenously expressed wild type PDK1 was constitutively repressed in the 1C11 cell system
(PDK1null-cells) upon cell transfection of a shRNA of the pdk1 gene [24] following the same
procedure as in [15]. The mutated S241 PDK1 mutant was built by polymerase chain reaction
and eight silent mutations were further introduced into the S241A pdk1 gene sequence corre-
sponding to the siRNA hybridization zone [15]. The mutated S241 pdk1 gene was cloned into
the pEBG-2T expression vector [66]. For expression of the S241A PDK1 mutant, PDK1null-
cells were transfected with 10 μg of the pEBG-2T construct as in [67] and left to grown for 36
h. Reconstituted cells were then lyzed and assayed for PDK1 expression, PDK1 activity, PDK1
interaction with ROCK-I and PDK1 phosphorylation by ROCK-I after cell metabolic labeling
with [32P]-orthophosphate.
Data analysis
An analysis of variance of the cell/animal response group was performed using Kaleidagraph
software (Synergy Software, Reading, PA, USA). Values are given as means ± s.e.m. Significant
responses (P< 0.05) are marked by symbols (#,,†,‡) and their corresponding P values are pro-
vided in figure legends. Survival times were analyzed by Kaplan-Meier survival analysis using a
log-rank test for curve comparisons. When non-specified experiments were performed in three
to five times in triplicates.
Supporting Information
S1 Fig. Inhibition of ROCK rescues neuritogenesis in prion-infected 1C11 cells. Phase pic-
tures of control 1C115-HT neuronal cells at day 4 of the serotonergic program and Fk- or 22L-
infected 1C11 cells induced to differentiate along the serotonergic pathway for 4 days in the
absence or presence of two distinct ROCK inhibitors, Y-27632 (100 μM) or dimethylfasudil
(2 μM). Scale bars, 50 μm.
(TIF)
S2 Fig. ROCK overactivation in 22-infected CGNs promotes TACE internalization in a
PDK1-dependent manner. (A) Immunofluorescent labeling of TACE at the surface of 22L-
infected CGNs treated or not with the ROCK inhibitor Y-27632 (100 μM) for 1 h versus unin-
fected cells. Scale bar, 50 μm. (B) Western-blot analysis (top) of the C1 fragment of PrP (C1)
and full-length PrP (Native) in 22L-infected CGNs treated or not with Y-27632 (100 μM) or a
combination of Y-27632 (100 μM) and TAPI-2 (100 μM) for 6h vs. uninfected CGNs. Ratio
(bottom) of C1/Native full-length PrP. (C) PDK1 activity in 22L-infected CGNs treated or not
with Y-27632 compared to uninfected CGNs. Values are the mean ± s.e.m.  P< 0.01 versus
non treated uninfected CGNs.  P< 0.01 versus non treated 22L-infected CGNs. # P< 0.05
versus non treated uninfected CGNs. ## P< 0.05 versus non treated 22L-infected CGNs.
### P< 0.05 versus 22L-infected CGNs treated with Y-27632.
(TIF)
S3 Fig. ROCK inhibition with dimethylfasudil attenuates prion disease in mice. (A) Sur-
vival curves of SHAM and 22L-inoculated mice via the intracerebellar route (i.c.b.) infused or
not with the ROCK inhibitor dimethylfasudil by intraperitoneal injection (i.p.) starting at 130
days after infection (3 mg per kg body weight per day; 0.25 μl h-1). n = 10 mice per group. (B)
Western blot and histogram quantifications for phosphorylated cofilin on Ser3 in 22L-infected
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mice infused or not with dimethylfasudil versus SHAMmice. n = 4 per condition. (C) Static
rod test between 130 and 160 days after infection in 22L-infected mice treated with dimethylfa-
sudil. n = 5 per group for mice treated with dimethylfasudil. n = 10 per group for untreated
mice. (D) Left, Western-blot for proteinase K-resistant PrPSc in brain extracts from SHAM and
22L-infected mice infused or not with dimethylfasudil. Right, post-mortem quantification of
proteinase K-resistant PrPSc in brains of 22L-infected mice treated or not with dimethylfasudil.
n = 7 for each condition. (E) ROCK immunoprecipitation followed by PDK1 western blotting
in cerebellar extracts of 22L-infected mice treated or not with dimethylfasudil versus SHAM
mice. n = 6 for each condition. (F) PDK1 activity in cerebellar extracts of 22L-infected mice
treated or not with dimethylfasudil versus SHAMmice. n = 6 for each condition. Values are
the mean ± s.e.m.  P< 0.01 versus SHAMmice.  P< 0.01 versus 22L-infected mice. #
P< 0.05 versus SHAMmice. ## P< 0.05 versus 22L-infected mice.
(TIF)
S4 Fig. Prion infection does not impact on TPH2 and SERT transcription in 1C11 precur-
sor cells. RT-PCR analysis of TPH2 and SERT transcripts in 1C11 and Fk-infected 1C11 cells
was performed as described in [47]. GAPDH was used for normalization.
(TIF)
S1 Table. Inhibition of ROCK with Y-27632 (100 μM) or dimethylfasudil (2 μM) restores
neuritogenesis in Fk-1C11 and 22L-1C11 cells exposed for 4 days to serotonergic inducers.
(TIF)
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